RNS Number : 5055Q
BSF Enterprise PLC
29 June 2022

29 June 2022

BSF Enterprise PLC

Interim Financial Statements

The Board of BSF Enterprise PLC is pleased to announce its Unaudited Interim Financial Statements for the six months ended 31 March 2022, which are available on the Company's website: www.bsfenterprise.com.

As required under Listing Rule 9.6.1 R, these have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC Via SEC Newgate below

Geoff Baker - Non-Executive Director

Graham Duncan - Chief Financial Officer

Shard Capital (Broker)

Damon Heath 020 7186 9952

Erik Woolgar

SEC Newgate (Financial Communications)

Bob Huxford 020 3757 6882

Elisabeth Cowell BSF@secnewgate.co.uk

George Esmond

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCBXGDLGGDDGDI